Banner
Males Are Genetically Wired To Beg Females For Food

Bees have the reputation of being incredibly organized and spending their days making sure our...

The Scorched Cherry Twig And Other Christmas Miracles Get A Science Look

Bleeding hosts and stigmatizations are the best-known medieval miracles but less known ones, like ...

$0.50 Pantoprazole For Stomach Bleeding In ICU Patients Could Save Families Thousands Of Dollars

The inexpensive medication pantoprazole prevents potentially serious stomach bleeding in critically...

Metformin Diabetes Drug Used Off-Label Also Reduces Irregular Heartbeats

Adults with atrial fibrillation (AFib) who are not diabetic but are overweight and took the diabetes...

User picture.
News StaffRSS Feed of this column.

News Releases From All Over The World, Right To You... Read More »

Blogroll

It's counterintuitive but young and middle-aged fibromyalgia patients report worse symptoms and poorer quality of life than older patients, accordin to Mayo Clinic results.

Fibromyalgia is a non-specific disorder, 
characterized by widespread musculoskeletal pain with fatigue, sleep, memory and mood issues that most often strikes women. The researchers presented their findings at the American College of Rheumatology annual meeting and suggest the disorder plays out differently among different age groups. 

Living with Type 1 and Type 2 diabetes means constant awareness of blood glucose (sugar) levels to ensure they remain stable.

People do this at home using electronic devices that read sugar levels in a tiny drop of blood but a team of German researchers has devised a new, non-invasive method; infrared laser light applied on top of the skin measures sugar levels in the fluid in and under skin cells.  

"This opens the fantastic possibility that diabetes patients might be able to measure their glucose level without pricking and without test strips," said lead researcher, Werner Mäntele, Ph.D. of Frankfurt's Institut für Biophysik, Johann Wolfgang Goethe-Universität.

At some point the exact number of particles in a group becomes irrelevant.

But does when a collection of elements forms a "heap" ?

In recent experiments using ultracold atoms, Heidelberg physicists succeeded in observing the transition to a many-body system well described by an infinite number of particles - a problem philosophers call the sorites paradox. The essential question is when a collection of elements forms a "heap". 

On Oct. 23rd, 2013, the sun emitted a solar flare, classified as an M9.4 flare on a scale from M1 to M9.9 - near the very top of the scale for M class flares.

Solar flares are powerful bursts of radiation. Harmful radiation from a flare cannot pass through Earth's atmosphere to physically affect humans on the ground, but when they are intense enough they can disturb the atmosphere in the layer where GPS and communications signals travel. Such radiation can disrupt radio signals for as long as the flare is ongoing, anywhere from minutes to hours.

Crystals form the basis for the penetrating icy blue glare of car headlights - they could also be fundamental to the future in solar energy technology?

Manufactured alloy crystals, such as indium gallium nitride or InGaN, form the light emitting region of LEDs, for illumination in the visible range, and of laser diodes (LDs) in the blue-UV range.  

In an article recently published in the journal Applied Physics Letters, researchers revealed the fundamental aspect of a new approach to growing InGaN crystals for diodes, which promises to move photovoltaic solar cell technology toward record-breaking efficiencies.

3K3A-APC, an experimental drug, appears to reduce brain damage and eliminate brain hemorrhaging in older stroke-afflicted mice and stroke-afflicted rats with co-morbid conditions such as hypertension, according to a new study.

The paper finds that 3K3A-APC may be used as a therapy for stroke in humans, either alone or in combination with the FDA-approved clot-busting drug therapy tPA (tissue plasminogen activator). Clinical trials to test the drug's efficacy in people experiencing acute ischemic stroke are expected to begin recruiting patients in the U.S. in 2014.